Ann: OPL Deepens Global AI Collaborations - Cardialysis & Evestia, page-2

Great news and a step in the right direction!!


Copied this from the announcement :

Cardialysis – Advancing Cardiovascular AI Insights
Cardialysis, a globally recognised full-service contract research organisation (CRO)
dedicated to cardiovascular clinical trials, has completed more than 400 trials across 1,400
investigative sites, enrolling over 200,000 patients to date. The company currently manages
approximately 40 active studies each year. Sponsors include Merck, AstraZeneca, Bayer,
Novartis, Abbott, Boston Scientific, Medtronic and GSK. Cardialysis has engaged TrialKey to